Thelansis

 Unresectable or metastatic pancreatic cancer (LAPC) is an advanced stage where the tumor cannot be completely removed through surgery or has spread to other body parts. Patients with LAPC often experience significant symptom burdens related to their primary malignancy. These symptoms may include pain, pancreatic insufficiency (resulting in difficulty digesting food), biliary obstruction (causing jaundice and related symptoms), and early satiety or gastric outlet obstruction (leading to feeling full quickly or difficulty eating). Most patients with pancreatic cancer are diagnosed at an advanced stage, with approximately 50% having metastatic disease and 25% to 35% having borderline or locally advanced disease. In terms of treatment options, gemcitabine plus nab-paclitaxel or FOLFIRINOX are commonly used as first-line chemotherapy regimens for patients with locally advanced or metastatic pancreatic cancer. Gemcitabine plus nab-paclitaxel has a median overall survival of 8.5 months, ...

 Unresectable or metastatic pancreatic cancer (LAPC) is an advanced stage where the tumor cannot be completely removed through surgery or has spread to other body parts. Patients with LAPC often experience significant symptom burdens related to their primary malignancy. These symptoms may include pain, pancreatic insufficiency (resulting in difficulty digesting food), biliary obstruction (causing jaundice and related symptoms), and early satiety or gastric outlet obstruction (leading to feeling full quickly or difficulty eating). Most patients with pancreatic cancer are diagnosed at an advanced stage, with approximately 50% having metastatic disease and 25% to 35% having borderline or locally advanced disease. In terms of treatment options, gemcitabine plus nab-paclitaxel or FOLFIRINOX are commonly used as first-line chemotherapy regimens for patients with locally advanced or metastatic pancreatic cancer. Gemcitabine plus nab-paclitaxel has a median overall survival of 8.5 months, ...